Advertisement

2016 Gastrointestinal Cancers Symposium

Pancreatic Cancer

‘Know Your Tumor’ Program Aids Patients With Pancreatic Cancer

Patients with pancreatic cancer can obtain molecular tumor profiling through the Pancreatic Cancer Action Network’s Know Your TumorSM precision medicine initiative, a partnership with Perthera, a pers...

Colorectal Cancer

Expert Point of View: Wells Messersmith, MD

Wells Messersmith, MD, Professor and Head of Medical Oncology and Director of the Gastrointestinal Cancer Program, University of Colorado, Denver, discussed the two studies. Closer Look at STEAM Dr. M...

Colorectal Cancer

Studies Evaluate Bevacizumab-Containing Regimens in Metastatic Colorectal Cancer

Two trials reported at the 2016 Gastrointestinal Cancers Symposium evaluated bevacizumab (Avastin)-containing regimens in the first-line treatment of metastatic colorectal cancer and supported some, b...

gastrointestinal cancer

Radiolabeled Somatostatin Analog May Represent A Paradigm Change in the Treatment of Neuroendocrine Tumors

A radiolabeled somatostatin analog compound, 177Lu-DOTA0-Tyr3-Octreotate (177Lu-Dotatate), reduced the risk of disease progression or death by 79% in the international phase III NETTER-1 population of...

gastrointestinal cancer

Carboplatin/Paclitaxel Tops Oxaliplatin/Capecitabine as Neoadjuvant Regimen for Esophageal Cancer

The United Kingdom’s phase II ­NEOSCOPE trial compared the toxicity and efficacy of two preoperative chemoradiation regimens—carboplatin/paclitaxel and oxaliplatin/capecitabine—and judged one to be th...

gastrointestinal cancer

Radiotherapy for Rectal Cancer: Study Reports No Risk for Subsequent Pelvic Tumors

Second malignancies were not more common among patients who underwent radiotherapy for rectal cancer. In fact, radiotherapy appeared to offer some degree of protection against subsequent cancers, acco...

Colorectal Cancer

Shorter Radiation Course May Benefit Patients With Locally Advanced Rectal Cancer

As neoadjuvant treatment for locally advanced rectal cancer, a shorter course of radiation therapy followed by chemotherapy may be as good as, or better than, standard chemoradiotherapy, according to ...

Pancreatic Cancer

Optimizing Outcomes in Pancreatic Cancer

Evidence has long supported a volume-outcome relationship for surgical resection of pancreatic cancer, yet surgery alone is not enough to prolong survival in patients with localized disease. James L. ...

gastrointestinal cancer

Receipt of Adjuvant Therapy at High-Volume Center Improves Survival in Patients With Pancreatic Cancer

Patients with pancreatic cancer who received adjuvant chemotherapy at a high-volume center had superior median and 5-year overall survival than did patients who were treated in a community setting, ac...

gastrointestinal cancer

Anti–PD-1/PD-L1 Antibodies Make Strong Showing in Gastrointestinal Cancers

Although the results may not yet be as impressive as those seen in melanoma, lung, and kidney cancers, monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) are producing response...

colorectal cancer

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study (German Language Version)

Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses in German the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratificatio...

colorectal cancer

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Results of the MAVERICC Study

Heinz-Josef Lenz, MD, of the USC Norris Comprehensive Cancer Center, discusses the findings of this phase II study of mFOLFOX6/bevacizumab vs FOLFIRI/bevacizumab with biomarker stratification in patie...

gastroesophageal cancer

Dung T. Le, MD, on Gastric or Gastroesophageal Junction Cancer: Results From the CheckMate-032 Trial

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric...

gastroesophageal cancer

Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results of the NETTER-1 Trial

Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival findings of this phase I...

gastroesophageal cancer

Yoon-Koo Kang, MD, PhD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Trial Results for T-DM1 vs a Taxane

Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previously treated HER2-posit...

gastroesophageal cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive, nonfunctional neur...

gastroesophageal cancer

Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial

Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pr...

colorectal cancer

Krzysztof Bujko, MD, on Rectal Cancer: Results of a Phase III Trial

Krzysztof Bujko, MD, of the Maria Skłodowska Curie Memorial Cancer Centre, discusses the results of a multicenter Polish study on neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer (Abstrac...

colorectal cancer

Daniel G. Haller, MD, on Colon and Rectal Cancers: A Global Overview

Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.

gastroesophageal cancer

Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028

Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).

hepatobiliary cancer

Richard S. Finn, MD, on Advanced Hepatocellular Carcinoma: Expert Perspective

Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).

solid tumors

Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive...

colorectal cancer

Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial (French Language Version)

Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490).

colorectal cancer

Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial

Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To view the French langu...

pancreatic cancer

James L. Abbruzzese, MD, on Pancreatic Cancer: Expert Perspective

James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.

Advertisement

Advertisement



Advertisement

click me